Literature DB >> 23917876

Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex.

Sajedeh Eftekhari1, Christopher A Salvatore, Renee C Gaspar, Rhonda Roberts, Stacey O'Malley, Zhizhen Zeng, Lars Edvinsson.   

Abstract

The cerebellum is classically considered to be mainly involved in motor processing, but studies have suggested several other functions, including pain processing. Calcitonin-gene-related peptide (CGRP) is a neuropeptide involved in migraine pathology, where there is elevated release of CGRP during migraine attacks and CGRP receptor antagonists have antimigraine efficacy. In the present study, we examined CGRP and CGRP receptor binding sites and protein expression in primate cerebellar cortex. Additionally, mRNA expression of the CGRP receptor components, calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1), was examined. In addition, expression of procalcitonin was studied. We observed high [(3)H]MK-3207 (CGRP receptor antagonist) binding densities in the molecular layer of rhesus cerebellar cortex; however, due to the limit of resolution of the autoradiographic image the exact cellular localization could not be determined. Similarly, [(125)I]CGRP binding was observed in the molecular layer and Purkinje cell layer of human cerebellum. CLR and RAMP1 mRNA was expressed within the Purkinje cell layer and some expression was found in the molecular layer. Immunofluorescence revealed expression of CGRP, CLR, and RAMP1 in the Purkinje cells and in cells in the molecular layer. Procalcitonin was found in the same localization. Recent research in the biology of cerebellum indicates that it may have a role in nociception. For the first time we have identified CGRP and CGRP receptor binding sites together with CGRP receptor expression through protein and mRNA localization in primate cerebellar cortex. These results point toward a functional role of CGRP in cerebellum. Further efforts are needed to evaluate this.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23917876     DOI: 10.1007/s12311-013-0509-4

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  45 in total

1.  Topography of cerebellar nuclear projections to the brain stem in the rat.

Authors:  T M Teune; J van der Burg; J van der Moer; J Voogd; T J Ruigrok
Journal:  Prog Brain Res       Date:  2000       Impact factor: 2.453

Review 2.  Calcitonin gene-related peptide in the brain, spinal cord, and some peripheral systems.

Authors:  T Hökfelt; U Arvidsson; S Ceccatelli; R Cortés; S Cullheim; A Dagerlind; H Johnson; C Orazzo; F Piehl; V Pieribone
Journal:  Ann N Y Acad Sci       Date:  1992-06-30       Impact factor: 5.691

3.  Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion.

Authors:  S Eftekhari; C A Salvatore; A Calamari; S A Kane; J Tajti; L Edvinsson
Journal:  Neuroscience       Date:  2010-05-22       Impact factor: 3.590

4.  Stimulation of cat cutaneous nociceptive C fibres causing tonic and synchronous activity in climbing fibres.

Authors:  C F Ekerot; O Oscarsson; J Schouenborg
Journal:  J Physiol       Date:  1987-05       Impact factor: 5.182

5.  Topographic localization of calcitonin gene-related peptide in the rat brain: an immunohistochemical analysis.

Authors:  Y Kawai; K Takami; S Shiosaka; P C Emson; C J Hillyard; S Girgis; I MacIntyre; M Tohyama
Journal:  Neuroscience       Date:  1985-07       Impact factor: 3.590

6.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 7.  The cerebellum and pain: passive integrator or active participator?

Authors:  Eric A Moulton; Jeremy D Schmahmann; Lino Becerra; David Borsook
Journal:  Brain Res Rev       Date:  2010-05-27

8.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

9.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

10.  Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.

Authors:  Christopher A Salvatore; Eric L Moore; Amy Calamari; Jacquelynn J Cook; Maria S Michener; Stacey O'Malley; Patricia J Miller; Cyrille Sur; David L Williams; Zhizhen Zeng; Andrew Danziger; Joseph J Lynch; Christopher P Regan; John F Fay; Yui S Tang; Chi-Chung Li; Nicole T Pudvah; Rebecca B White; Ian M Bell; Steven N Gallicchio; Samuel L Graham; Harold G Selnick; Joseph P Vacca; Stefanie A Kane
Journal:  J Pharmacol Exp Ther       Date:  2010-01-11       Impact factor: 4.030

View more
  10 in total

Review 1.  Targeting CGRP: A New Era for Migraine Treatment.

Authors:  Stephanie Wrobel Goldberg; Stephen David Silberstein
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

2.  CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

Authors:  Lars Edvinsson
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

3.  Calcitonin receptor antibody validation and expression in the rodent brain.

Authors:  Erica R Hendrikse; Tayla A Rees; Zoe Tasma; Christelle Le Foll; Thomas A Lutz; Andrew Siow; Peter J Wookey; Christopher S Walker; Debbie L Hay
Journal:  Cephalalgia       Date:  2022-04-11       Impact factor: 6.075

4.  CGRP Administration Into the Cerebellum Evokes Light Aversion, Tactile Hypersensitivity, and Nociceptive Squint in Mice.

Authors:  Mengya Wang; Thomas L Duong; Brandon J Rea; Jayme S Waite; Michael W Huebner; Harold C Flinn; Andrew F Russo; Levi P Sowers
Journal:  Front Pain Res (Lausanne)       Date:  2022-04-25

5.  Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier.

Authors:  Rodrigo Noseda; Aaron J Schain; Agustin Melo-Carrillo; Jason Tien; Jennifer Stratton; Fanny Mai; Andrew M Strassman; Rami Burstein
Journal:  Cephalalgia       Date:  2019-12-19       Impact factor: 6.292

Review 6.  CGRP and the Trigeminal System in Migraine.

Authors:  Smriti Iyengar; Kirk W Johnson; Michael H Ossipov; Sheena K Aurora
Journal:  Headache       Date:  2019-04-14       Impact factor: 5.887

7.  Cortical mechanisms in migraine.

Authors:  Wei Dai; Ren-Hao Liu; Enchao Qiu; Yinglu Liu; Zhiye Chen; Xiaoyan Chen; Ran Ao; Min Zhuo; Shengyuan Yu
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

Review 8.  The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.

Authors:  Smriti Iyengar; Michael H Ossipov; Kirk W Johnson
Journal:  Pain       Date:  2017-04       Impact factor: 7.926

Review 9.  Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Authors:  Philip R Holland; Peter J Goadsby
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 10.  New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.

Authors:  Irene Simonetta; Renata Riolo; Federica Todaro; Antonino Tuttolomondo
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.